Search for: [Abstract = "kers in moderate OSA patients. Forty\-six individuals were included into the open\-label interventional study, carried out in 27 moderate OSA patients \(24 men and 4 women\) \(OSA group\) and 19 apparently healthy people who constituted the control group. The control group was well matched with the OSA group by the demographic variables, body mass index, arterial systolic and diastolic blood pressure and oxygen saturation. For the patients with moderate OSA the KlearwayTM oral appliance was individually made. In the OSA group the polisomnography examination, baseline laboratory tests, pulmonary function tests \(spirometry\) and the measurements of the inflammatory and hemostatic markers \(fibrinogen, C\-reactive protein \[CRP\], interleukin 1 beta \[IL\-1 ß\], interleukin 10 \[IL\-10\], interleukin 6 \[IL\-6\], plasminogen activator inhibitor\-1 \[PAI\-1\], P\-selectin, D\-dimer, thrombin\-antithrombin complex \[TAT\] and activated thrombin\- activatable fibrinolysis inhibitor \[TAFIa\]\) was carried out at baseline and then after 3 and 6 months of oral appliance treatment\; in the control group the same procedures were performed twice at baseline and after 6 months of the study. A final analysis included 23 OSA patients and 19 healthy subjects. As compared to the control group, in the moderate OSA group the higher baseline levels of IL\-1 ß \(0.34 \[pg\/ml\] vs 0.24\; p=0.03\), IL\- 10 \(5.69 \[pg\/ml\] vs 3.96\; p=0.01\), P"]

Number of results: 1